Recombinant Nucleic Acid Constructs for Targeted Viral Load Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for viral infections, such as hepatitis B, are often ineffective or costly, and existing therapies struggle to target and eliminate the viral load due to the complex life cycles of viruses, which are intimately connected to host cell processes.
Innovation Solution
The use of recombinant nucleic acid constructs or replication incompetent virus-like particles encoding chemokines, cytokines, or apoptosis-inducing proteins, such as Caspase 9, which are designed to be transcribed only in the presence of a viral polymerase, allowing for targeted killing of virally infected cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antiviral therapies are used, then viral replication in cytoplasmic capsids is inhibited, but nuclear cccDNA is not reduced or destroyed
Solution Approach 1:
The patent uses a recombinant nucleic acid construct as an intermediary that delivers apoptosis-inducing proteins specifically to infected cells. This construct acts as a mediator between the therapeutic goal (killing infected cells) and the biological barrier (cccDNA persistence), enabling targeted destruction of infected cells without directly attacking the cccDNA reservoir.
Solution Approach 2:
The invention extracts the apoptosis-inducing function from the complex viral life cycle by using a separate recombinant construct that expresses pro-apoptotic proteins. This separates the therapeutic action (inducing apoptosis) from the viral replication process, allowing targeted killing of infected cells independent of the complex viral machinery.
2Adaptability or versatility
If recombinant nucleic acid constructs encoding apoptosis-inducing proteins are used, then infected cells are selectively killed, but the treatment mechanism is fundamentally different from conventional therapies
Solution Approach 1:
The recombinant nucleic acid construct exhibits local quality by expressing apoptosis-inducing proteins specifically in infected cells through viral polymerase-dependent transcription. This creates a localized therapeutic effect only where needed (in infected cells) while leaving uninfected cells unaffected, achieving high adaptability without systemic complexity.
3Reliability
If nucleoside analogue antiviral drugs are used, then HBV DNA replication is inhibited, but the treatment is ineffective or costly for much of the world
Solution Approach 1:
The recombinant nucleic acid construct functions as a disposable therapeutic agent that delivers its effect through transient expression of apoptosis-inducing proteins. This approach replaces expensive, long-term nucleoside analogue therapy with a potentially more accessible single or limited-dose treatment that achieves viral load reduction through immune-mediated clearance of infected cells.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach provides a fundamentally different treatment mechanism that can effectively reduce or eliminate viral load by inducing apoptosis in infected cells, while sparing uninfected cells, thus offering a promising solution for challenging viral infections.
Implementation Method 1
recombinant nucleic acid constructs or a replication incompetent virus-like particle encoding a chemokine, cytokine, or apoptosis inducing protein (e.g. Caspase 9 (Casp9)), in a form which will only be transcribed in the presence of a viral polymerase
Implementation Method 2
encoding a chemokine, a cytokine, an apoptosis inducing protein, or a combination thereof... providing a fundamentally different treatment mechanism that can effectively reduce or eliminate viral load by inducing apoptosis in infected cells
Data Source
AI summary
The disclosure provides methods and compositions utilizing recombinant nucleic acid constructs or a replication incompetent virus-like particle encoding a chemokine, cytokine, or apoptosis inducing protein (e.g. Caspase 9 (Casp9)), or other toxins in a form which can only be transcribed in the presence of a viral polymerase. These methods can be adapted to target many viral infections and reduce or eliminate viral load, and provide a fundamentally different treatment for viral infections.